9014 Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with high risk of recurrence after surgery. Adjuvant radiation therapy (RT) and/or chemotherapy are commonly used, but with limited data regarding their effectiveness. To assess the impact of adjuvant RT and chemotherapy on MCC survival, we performed a retrospective analysis of the National Cancer Data Base (NCDB) that has the largest known cohort of MCC patients (pts). NCDB also collects data on adjuvant chemotherapy and comorbidity status (Charlson/Deyo score) that were missing in a prior study of outcomes with adjuvant RT in 1,487 pts in the Surveillance, Epidemiology, and End Results (SEER) database. Methods: 6,908 MCC pts with stage, treatment and survival data available were included in this analysis. Multiple covariate analyses were conducted for overall survival outcomes with various treatment modalities while adjusting for age, sex, comorbidity score, and other therapies. Results: In pts with localized MCC (AJCC stage I N=3,369; stage II N=1,474), surgery plus RT was associated with significantly better survival than seen with surgery alone (Stage I HR 0.75 [95% CI 0.67–0.83], p<0.0001; Stage II HR 0.77 [95% CI 0.67–0.90], p=0.0006). In pts with nodal involvement (stage III N=2,065), adjuvant chemotherapy was not associated with improved or worsened survival versus no chemotherapy (HR 1.07 [95% CI 0.93–1.22], p=0.37). Even among a subgroup of stage III pts aged < 65 and with comorbidity score=0, adjuvant chemotherapy was not associated with improved survival. Conclusions: This retrospective study analyzed the largest MCC dataset to date for outcomes with adjuvant therapy. These results suggest improved survival with the use of adjuvant RT in stage I-II MCC pts. Adjuvant RT or chemotherapy were not associated with improved survival in stage III MCC pts. Despite the ability to assess comorbidity scores, treatment biases that could have accounted for some of the observed effects cannot be directly addressed, and prospective multicenter evaluations of adjuvant RT and chemotherapy remain warranted. Until then, multidisciplinary evaluation and individualized care is appropriate for all pts with MCC.